Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader…
